Allergies News and Research

Latest Allergies News and Research

Research collaboration identifies antibody that limits the severity of coronavirus infections

A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.

2 Nov 2021

Scientists identify compound that shows potential in easing the symptoms of coronavirus infections

By studying a disease caused by a close cousin of the virus behind COVID-19, a team of scientists has identified a compound that shows potential in easing the symptoms of coronavirus infections.

1 Nov 2021

New genetic epidemiology tool provides detailed information about viruses, coinfections

With mask wearing and social distancing on the decline and the cold and flu season upon us, researchers have developed a viral panel that enables the simultaneous testing for SARS-CoV-2 along with numerous common respiratory viruses, that tells us whether other viruses also are at play in patients hard hit by COVID.

1 Nov 2021

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.

1 Nov 2021

Prompt procurement and rapid pace of vaccination likely to have a greater impact than vaccine efficacy

For low- and middle-income countries, a COVID-19 vaccination program built on prompt procurement, effective on-the-ground distribution, and a rapid pace of vaccination (the total number of doses given daily) is likely to have a greater public health impact than one focused on relatively small differences in vaccine efficacy, according to a study led by researchers at Massachusetts General Hospital.

30 Oct 2021

NIH study identifies distinct mechanisms of long-term HIV control in two people after treatment disruption

Research led by scientists at the National Institutes of Health has identified two distinct ways that people with HIV can control the virus for an extended period after stopping antiretroviral therapy (ART) under medical supervision.

29 Oct 2021

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Kawasaki disease (KD) is rare, with fewer than 6,000 diagnosed cases per year in the United States. It is most common in infants and young children and causes inflammation in the walls of some blood vessels in the body.

27 Oct 2021

Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques

Researchers in the United States have conducted a study showing that Moderna’s coronavirus disease 2019 (COVID-19) vaccine provided durable protection against the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in rhesus macaques.

26 Oct 2021

Cholesterol-lowering drugs not helpful in reducing COVID-related mortality or severity

In the worldwide effort to battle SARS-CoV-2, the virus that causes COVID-19, researchers have often turned to medications used as therapies for other conditions in the hopes of finding ones that either kill the coronavirus or lessen the impacts from its infection.

26 Oct 2021

NIH invests $74.5 million to advance data science research and spur health discoveries across Africa

The National Institutes of Health is investing about $74.5 million over five years to advance data science, catalyze innovation and spur health discoveries across Africa.

26 Oct 2021

Researchers investigate SARS-CoV-2 specific immunity in young Swedish adults

Researchers at Karolinska Institutet in Sweden have analyzed the presence of SARS-CoV-2-specific antibodies and memory cells of the immune system in young adults.

25 Oct 2021

Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues

A new study aimed to determine whether ACE2 targeting drugs change the tissue levels of ACE2 in healthy mice.

25 Oct 2021

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

21 Oct 2021

Duke awarded NIAID funding to develop the next generation of pan-coronavirus vaccines

The National Institute of Allergy and Infectious Diseases has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.

21 Oct 2021

Booster dose of COVID-19 vaccine significantly increases neutralizing antibodies in rhesus macaques

A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues.

21 Oct 2021

Pitt researchers to contribute to building an atlas of cellular senescence

Most cells throughout the body can divide and multiply to replace old cells and repair damaged tissue, but in response to certain stresses, cells can lose their ability to proliferate. These so-called senescent cells accumulate with age and may contribute to cancer and age-related disorders, such as chronic lung disease, cardiovascular disease, frailty and dementia, by pumping out signals that damage neighboring tissues.

21 Oct 2021

Interferon beta-1a plus remdesivir not superior to remdesivir alone in hospitalized COVID-19 patients

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia.

18 Oct 2021

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Aberrant CXCR4/CXCL12 signaling is involved in many pathophysiological processes such as cancer and inflammatory diseases. A natural fragment of serum albumin, named EPI-X4, has previously been identified as endogenous peptide antagonist andinverse agonistof CXCR4 and is a promising compound for the development of improved analogues for the therapy of CXCR4-associated diseases.

18 Oct 2021

Formula milk trials have a high risk of bias, review finds

Formula milk trials have a high risk of bias, authors almost always report favorable conclusions, transparency is lacking, and findings are selectively reported, finds a review of evidence from recently published trials in The BMJ today.

14 Oct 2021

Small portion of COVID-19 patients infectious long-term

In late December 2019, a novel pneumonia-like lung infection was reported in the Chinese province of Hubei. This, in turn, led to the ongoing coronavirus disease-19 (COVID-19) pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to SARS (Severe Acute Respiratory Syndrome) and MERS (the Middle East Respiratory Syndrome Coronavirus).

13 Oct 2021

Allergies News and Research

Latest Allergies News and Research

Research collaboration identifies antibody that limits the severity of coronavirus infections

Scientists identify compound that shows potential in easing the symptoms of coronavirus infections

New genetic epidemiology tool provides detailed information about viruses, coinfections

COVID-19 antibody levels stay more durable in vaccinated people with prior SARS-CoV-2 infection

Prompt procurement and rapid pace of vaccination likely to have a greater impact than vaccine efficacy

NIH study identifies distinct mechanisms of long-term HIV control in two people after treatment disruption

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Moderna’s COVID-19 vaccine provides durable protection against SARS-CoV-2 delta in macaques

Cholesterol-lowering drugs not helpful in reducing COVID-related mortality or severity

NIH invests $74.5 million to advance data science research and spur health discoveries across Africa

Researchers investigate SARS-CoV-2 specific immunity in young Swedish adults

Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues

Investigational inhaled COVID-19 treatment graduates to phase 3 in ACTIV-2 trial

Duke awarded NIAID funding to develop the next generation of pan-coronavirus vaccines

Booster dose of COVID-19 vaccine significantly increases neutralizing antibodies in rhesus macaques

Pitt researchers to contribute to building an atlas of cellular senescence

Interferon beta-1a plus remdesivir not superior to remdesivir alone in hospitalized COVID-19 patients

New class of CXCR4 antagonists could prevent airway inflammation and atopic dermatitis

Formula milk trials have a high risk of bias, review finds

Small portion of COVID-19 patients infectious long-term

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Allergies News and Research

Latest Allergies News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in